NCT05536141 2026-03-30
ARC-20
Arcus Biosciences, Inc.
Phase 1 Recruiting
Clinical Trials
17 trialsNCT07397611 2026-03-20
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05633667 2026-03-17
VELOCITY-Lung
Gilead Sciences
Phase 2 Recruiting
NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting
NCT06759649 2026-02-27
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Compugen Ltd
Phase 1 Recruiting
NCT06048133 2026-01-23
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT05007782 2025-12-29
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT06238921 2025-12-05
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting
NCT05024097 2025-08-27
PANTHER
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT05915442 2025-05-20
SBRT-AMICO
Columbia University
Phase 2 Recruiting
NCT06532565 2025-05-16
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT06431633 2025-04-10
ARIAN
Fundación GECP
Phase 3 Recruiting
NCT06155396 2024-02-28
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06055738 2023-09-28
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Tang-Du Hospital
Phase 2 Recruiting
NCT05909436 2023-06-18
Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
Guangzhou Gloria Biosciences Co., Ltd.
Phase 1/2 Recruiting
NCT05872724 2023-05-24
Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
Suzhou Municipal Hospital
Phase 2 Recruiting